Dr. Sayar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1111 Ronald Reagan Pkwy
Avon, IN 46123Phone+1 317-944-0920Fax+1 317-968-1137
Education & Training
University of New Mexico School of MedicineFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2003 - 2004
Tehran University of Medical Sciences School of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 2011 - 2026
IN State Medical License 2007 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Apr 01
- Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype Start of enrollment: 2012 Feb 10
Publications & Presentations
PubMed
- 3 citationsLong-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-c...Andrew H Wei, Hartmut Döhner, Hamid Sayar, Farhad Ravandi, Pau Montesinos
American Journal of Hematology. 2023-04-01 - 12 citationsManagement of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialFarhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock
Journal of Hematology & Oncology. 2021-08-28 - 6 citationsDoes race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms?Andrew M. Peseski, Antoine N. Saliba, Sandra K. Althouse, Hamid Sayar
Hematology/oncology and Stem Cell Therapy. 2021-02-11
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
